BENAZEPRIL 10 MG
BENAZEPRIL HYDROCHLORIDE : 10 MG · DIN 02290340 · AA PHARMA INC
Health Canada status: MARKETED
What is BENAZEPRIL?
BENAZEPRIL 10 MG contains BENAZEPRIL HYDROCHLORIDE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02290340, held by AA PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 25-Jun-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BENAZEPRIL used for?
Treatment of mild to moderate essential hypertension. May be used alone or with thiazide diuretics. Not recommended for congestive heart failure or renovascular hypertension.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02290340 |
|---|---|
| Brand name | BENAZEPRIL |
| Generic / active ingredient | BENAZEPRIL HYDROCHLORIDE : 10 MG |
| Manufacturer | AA PHARMA INC |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09AA07 BENAZEPRIL |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 25-Jun-2012 |
How is it administered?
Initial: 10 mg once daily. Maintenance: 20 mg daily. Max: 40 mg/day. Adjust for renal impairment (CrCl < 30 mL/min: start at 5 mg). Correct volume/salt depletion before starting.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Section 11 header present but content missing), though typically room temperature for this class.
How is it supplied?
Bottles of 100 tablets.
Contraindications
Hypersensitivity to benazepril or ACE inhibitors; history of angioedema; pregnancy/breastfeeding; concomitant use with neprilysin inhibitors or aliskiren (in diabetes/renal impairment).
Warnings and precautions
Serious: Fetal injury/death; risk of renal failure in susceptible patients. Warnings: Angioedema (can be fatal), hypotension, hyperkalemia, neutropenia, and cough.
Is BENAZEPRIL in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by AA PHARMA INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C09AA07 BENAZEPRIL. 3 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BENAZEPRIL | 20 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02273918 |
| BENAZEPRIL | 5 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02290332 |
| LOTENSIN 10MG | 10 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | DIN 00885843 |
| LOTENSIN 20MG | 20 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | DIN 00885851 |
| LOTENSIN 5MG | 5 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | DIN 00885835 |
| PMS-BENAZEPRIL | 10 MG | TABLET | PHARMASCIENCE INC | CANCELLED PRE MARKET | DIN 02231550 |
| PMS-BENAZEPRIL | 20 MG | TABLET | PHARMASCIENCE INC | CANCELLED PRE MARKET | DIN 02231551 |
| PMS-BENAZEPRIL | 5 MG | TABLET | PHARMASCIENCE INC | CANCELLED PRE MARKET | DIN 02231548 |
Who else supplies BENAZEPRIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BENAZEPRIL appears in 17 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.